Search clinical trials for: PF-06865571 Monotherapy

Total 1709 results

Pfizer

Completed

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

United States
Pfizer

Completed

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Healthy Participants

United States
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Healthy Subjects

United States, Belgium
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Completed

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Healthy Participants

Belgium
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Pfizer

Completed

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

Healthy

Belgium
Pfizer

Completed

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

United States
Pfizer

Completed

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Pfizer

Completed

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

Healthy

United States
Pfizer

Completed

Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics

Healthy Volunteers

Belgium
Pfizer

Active, not recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

United States, China, Japan, Mexico, Bulgaria, Argentina
Pfizer

Terminated

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

United States
Pfizer

Completed

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Pfizer

Completed

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

Healthy

United States
Xizang Haisco Pharmaceutical Co., Ltd

Recruiting

A Study for HSK39775 in Participants With Solid Tumors

Advanced Solid Tumors

China
University of California, San Francisco

Not yet recruiting

Two-fraction HDR Monotherapy for Localized Prostate Cancer

Prostate Adenocarcinoma | Localized Prostate Carcinoma

United States
Masonic Cancer Center, University of Minnesota

Active, not recruiting

HCW9218 in Select Advanced Solid Tumors

Solid Tumor

United States
Peking Union Medical College Hospital

Completed

Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis

Chronic Periaortitis | Tocilizumab Monotherapy

China
Groupe d'Etude Therapeutique des Affections Inflammatoires...

Active, not recruiting

Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab (CURE)

CD

France, Belgium
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom
PharmAbcine
C&R Research, Inc.

Recruiting

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

Korea, Republic of
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer

Non-small Cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.

Completed

A Trial of ZL-1201 in Subjects With Advanced Cancer

Advanced Cancer

United States, China
Seoul National University Hospital
Threshold Pharmaceuticals

Completed

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Brigham and Women's Hospital

Recruiting

Ultrasound Therapy In Cardiac Amyloidosis (UTICA)

Amyloidosis Cardiac

United States
Children's Hospital of Philadelphia
Bayer

Recruiting

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Cancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, Thyroid

United States
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Children's Hospital of Philadelphia
Eli Lilly and Company; United States Department of Defense

Not yet recruiting

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) (RAISE)

Cancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, Thyroid
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
Tongji Hospital
First Affiliated Hospital Xi'an Jiaotong University; Wuhan Union Hospital,... and other collaborators

Recruiting

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Ovarian Cancer

China
Incyte Corporation

Terminated

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin's Lymphoma
Pfizer

Completed

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

Healthy

United States
University of Florida

Completed

Potato Fiber and Gastrointestinal Function: Phase 3

Gastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit Time

United States
Shenzhen TargetRx, Inc.
Institute of Hematology & Blood Diseases Hospital, China

Recruiting

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Non Hodgkin Lymphoma | Hematologic Malignancy | Acute Lymphoblastic Leukemia, Adult

China
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Japan
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Visus Therapeutics

Completed

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

Presbyopia

United States
Pfizer

Not yet recruiting

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Healthy Participants
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Bryan Schneider, MD
Hoosier Cancer Research Network; Walther Cancer Institute; Vera Bradley Foundation... and other collaborators

Completed

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Breast Cancer | Malignant Neoplasm of Breast

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States

3

Subscribe